This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
Capital at risk
overfunded
Stablepharma
174%
Raised
£1,310,090
Investors
524
Target
£750,000
Equity
11.58%
Pre-money valuation
£10,000,000

50% of vaccines are wasted, mainly due to poor refrigeration. Stablepharma's invention is designed to deliver a disruptive solution that can eliminate waste & supply life-saving vaccines to all without refrigeration. Proof of Concept has been achieved & investment is now sought for commercialisation.

  • R&D completed Proof of Concept verified by a WHO accredited Laboratory
  • Current project plan is Clinical Trials in Humans on a 12 month timeline
  • Designed to be compatible with c. 90 existing and approved vaccines
  • The WHO & NGO’s are on record for the acute need for stable vaccines

Idea

The Stablepharma Story
Using StablevaX® is simple – just add water to re hydrate the sponge that contains the correct dose of vaccine, whilst dehydrated the vaccine is totally stable and safe.
Using StablevaX® is simple – just add water to re hydrate the sponge that contains the correct dose of vaccine, whilst dehydrated the vaccine is totally stable and safe.
R&D completed with Proof of Concept verified at NIBSC - a WHO accredited Laboratory
R&D completed with Proof of Concept verified at NIBSC - a WHO accredited Laboratory
This patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO
This patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO
The WHO & NGO’s are on record for the acute need for stable vaccines
The WHO & NGO’s are on record for the acute need for stable vaccines
Pilot Scale production facilities will be located in Delemont, Switzerland under the management of Dr Anil Chawla
Pilot Scale production facilities will be located in Delemont, Switzerland under the management of Dr Anil Chawla
Under the supervision of our R&D Director Dr Arcadio Garcia de Castro we have R&D Laboratories & Toxicology facilities located in Madrid
Under the supervision of our R&D Director Dr Arcadio Garcia de Castro we have R&D Laboratories & Toxicology facilities located in Madrid
Animal vaccines - we will investigate the early revenue potential in the animal vaccine market
Animal vaccines - we will investigate the early revenue potential in the animal vaccine market
The WHO reports over 50% vaccine wastage - This invention is designed to deliver a disruptive solution to avoid refrigeration, eliminate waste providing life-saving vaccines to all who need them.
The WHO reports over 50% vaccine wastage - This invention is designed to deliver a disruptive solution to avoid refrigeration, eliminate waste providing life-saving vaccines to all who need them.
SP's first investor was Dr Inga Zaytseva, for us she encapsulated the ideal shareholder vision; ‘’I am investing in Stablepharma, 50% for the impact on World Health, and 50% because of the investment''
SP's first investor was Dr Inga Zaytseva, for us she encapsulated the ideal shareholder vision; ‘’I am investing in Stablepharma, 50% for the impact on World Health, and 50% because of the investment''

'Every 20 seconds a child dies from a vaccine-preventable disease'

Gates Foundation

Problem: Vaccines are perishable, requiring constant & precise refrigeration from the manufacturer to the patient, be it in a UK Hospital or a clinic in Africa. The WHO estimates that c 50% of all vaccines are wasted in spite of c $400m p.a. spent on the global Cold Chain

Solution: this patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO. It’s an important breakthrough that can save many lives.

Stablevax comprises approved vaccines which are dried from a solution of stabilising sugar into a special sponge stored in a normal syringe. They are pre-dosed and safe, to use you just add water. Stable vaccines will be manufactured at c. the same price as current products

£600k of equity funding enabled completion of R&D to the Proof of Concept milestone independently verified by the National Institute of Biological Standards and Controls (NHS & WHO-accredited Laboratory)

The current project plan involves the Tetanus vaccine processed through Clinical Trials in Humans, this achievement will significantly enhance the value of the invention and allow us to set up pilot scale production as the last step to commercialisation to enter the c. $36 bn human vaccine market and exploit this truly disruptive invention

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Stablepharma pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Stablepharma has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.

Investing
Raising
About us
Legal
  • Download on the App Store
  • Get it on Google Play
Crowdcube Capital Ltd is authorised and regulated by the Financial Conduct Authority (No. 650205).